February 10, 2016

FDA panel backs lower-cost version of J&J's top-selling drug

byMatthew Perrone

Federal health advisers have endorsed a lower-cost version of Johnson & Johnson's blockbuster drug Remicade, a pricey biotech medicine used to treat a number of inflammatory diseases.

The non-binding recommendation could clear the way for the cheaper medication from Celltrion, which would only be the second in a new class of quasi-generic biotech drugs to reach the U.S. market. These drugs, already available in Europe, have the potential to generate billions of dollars in savings for insurers, doctors and patients in coming years.

The FDA panel of outside experts agreed that Celltrion's version of the drug was highly similar to original Remicade, the standard set by the FDA for approval. But some of the experts said they would like to see more information on the drug's performance against certain diseases.

Citation: FDA panel backs lower-cost version of J&J's top-selling drug (2016, February 10) retrieved 19 April 2024 from https://medicalxpress.com/news/2016-02-fda-panel-lower-cost-version-jj.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Court ruling clears way for Novartis' low-cost biotech drug

0 shares

Feedback to editors

Researchers discover new therapeutic target for non-small cell lung cancer

9 hours ago

Immune cells carry a long-lasting 'memory' of early-life pain

10 hours ago

Cannabis legalization and rising sales have not contributed to increase in substance abuse, study finds

10 hours ago

No negative impact from prolonged eye patching on child's development or family stress levels

10 hours ago

COVID-19 booster immunity lasts much longer than primary series alone, study shows

10 hours ago

Study finds that human neuron signals flow in one direction

11 hours ago

A common pathway in the brain that enables addictive drugs to hijack natural reward processing identified

12 hours ago

Scientists identify airway cells that sense aspirated water and acid reflux

12 hours ago

Environment may influence metacognitive abilities more than genetics

12 hours ago

Contracting RSV before age two can cause long-term lung changes and impairment

12 hours ago

Load comments (0)

FDA panel backs lower-cost version of J&J's top-selling drug

Researchers discover new therapeutic target for non-small cell lung cancer

Immune cells carry a long-lasting 'memory' of early-life pain

Cannabis legalization and rising sales have not contributed to increase in substance abuse, study finds

No negative impact from prolonged eye patching on child's development or family stress levels

COVID-19 booster immunity lasts much longer than primary series alone, study shows

Study finds that human neuron signals flow in one direction

A common pathway in the brain that enables addictive drugs to hijack natural reward processing identified

Scientists identify airway cells that sense aspirated water and acid reflux

Environment may influence metacognitive abilities more than genetics

Contracting RSV before age two can cause long-term lung changes and impairment

Court ruling clears way for Novartis' low-cost biotech drug

FDA approves first lower-cost biotech drug (Update)

FDA panel endorses first lower-cost biotech drug

FDA lays out proposal for naming lower-cost biotech drugs (Update)

FDA advisers unanimously back J&J hepatitis C drug

FDA panel backs first-in-class cholesterol drug

Which treatments for malnutrition's long-term effects could help reduce mortality and health outcomes for children

Antipsychotics for dementia linked to more harms than previously acknowledged

Ketamine produces wide variety of responses in the brain, researchers find

New drug may slow rapid progression of Parkinson's disease

Large study finds antibiotics aren't effective for most lower tract respiratory infections

Epilepsy drug prevents brain tumors in mice with neurofibromatosis type 1

Phys.org

Tech Xplore

Science X

FDA panel backs lower-cost version of J&J's top-selling drug

Researchers discover new therapeutic target for non-small cell lung cancer

Immune cells carry a long-lasting 'memory' of early-life pain

Cannabis legalization and rising sales have not contributed to increase in substance abuse, study finds

No negative impact from prolonged eye patching on child's development or family stress levels

COVID-19 booster immunity lasts much longer than primary series alone, study shows

Study finds that human neuron signals flow in one direction

A common pathway in the brain that enables addictive drugs to hijack natural reward processing identified

Scientists identify airway cells that sense aspirated water and acid reflux

Environment may influence metacognitive abilities more than genetics

Contracting RSV before age two can cause long-term lung changes and impairment

Related Stories

Court ruling clears way for Novartis' low-cost biotech drug

FDA approves first lower-cost biotech drug (Update)

FDA panel endorses first lower-cost biotech drug

FDA lays out proposal for naming lower-cost biotech drugs (Update)

FDA advisers unanimously back J&J hepatitis C drug

FDA panel backs first-in-class cholesterol drug

Recommended for you

Which treatments for malnutrition's long-term effects could help reduce mortality and health outcomes for children

Antipsychotics for dementia linked to more harms than previously acknowledged

Ketamine produces wide variety of responses in the brain, researchers find

New drug may slow rapid progression of Parkinson's disease

Large study finds antibiotics aren't effective for most lower tract respiratory infections

Epilepsy drug prevents brain tumors in mice with neurofibromatosis type 1

Newsletter sign up

Donate and enjoy an ad-free experience